Literature DB >> 21775141

Does primary tumor resection improve outcomes for patients with incurable advanced breast cancer?

Susumu Shibasaki1, Hiromi Jotoku, Kenichi Watanabe, Masato Takahashi.   

Abstract

BACKGROUND: Metastatic breast cancer (MBC) is considered incurable, and surgery has only limited benefit in the treatment of this disease. However, recent reports have indicated that primary tumor resection may improve patient outcomes. We retrospectively analyzed the surgical benefits and prognostic factors for patients with MBC who were treated at our center.
METHODS: Ninety-two women, who had tumors of greater than 5 cm and distant metastasis at diagnosis, were included in this study. The effect of surgical treatment on survival was evaluated. Patient demographics and tumor characteristics were also investigated.
RESULTS: Thirty-six patients had surgery for resection of primary tumors. There were no substantive differences between individuals, or between tumor characteristics, for patients who underwent surgery versus patients who did not. The median survival time for surgically treated patients was 25.0 months versus 24.8 months for patients who did not undergo surgical resection (P=0.352). Only three patients relapsed within three months of surgery. For the remaining majority of patients, primary tumor resection gave some relief from the often severe symptoms that come from harboring a large tumor for an extended time. In univariate and subsequent multivariate analyses of predictive indicators, a diagnosis of triple-negative breast cancer and/or metastasis to more than three sites was significantly associated with a severe prognosis.
CONCLUSION: Primary tumor resection failed to prolong overall survival times in patients with incurable advanced breast cancer that was greater than 5 cm. However, surgery did improve the quality of life in patients who were expected to have a relatively long prognosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21775141     DOI: 10.1016/j.breast.2011.06.006

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  6 in total

1.  Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011.

Authors:  Alexandra Thomas; Seema A Khan; Elizabeth A Chrischilles; Mary C Schroeder
Journal:  JAMA Surg       Date:  2016-05-01       Impact factor: 14.766

2.  Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma.

Authors:  S Samiee; P Berardi; N Bouganim; L Vandermeer; A Arnaout; S Dent; D Mirsky; M Chasen; J M Caudrelier; M Clemons
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

3.  Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis.

Authors:  Ritika Gera; Hiba E L Hage Chehade; Umar Wazir; Salim Tayeh; Abdul Kasem; Kefah Mokbel
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

4.  Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study.

Authors:  Deyue Liu; Jiayi Wu; Caijin Lin; Lisa Andriani; Shuning Ding; Kunwei Shen; Li Zhu
Journal:  Front Oncol       Date:  2020-12-02       Impact factor: 6.244

5.  Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.

Authors:  Athénaïs Grave; Julie Blanc; Berardino De Bari; Mandy Pernot; Fatiha Boulbair; Monique Noirclerc; Angélique Vienot; Stefano Kim; Christophe Borg; Jihane Boustani
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

6.  Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study.

Authors:  Sun Jianna; Kong Lingjun; Feng Nana; Liu Hong; Ren Chongxi
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.